Pharmaceutical Calculation Suite
Determines the maximum acceptable residue of one product that can remain on equipment before manufacturing the next product, ensuring safety and regulatory compliance.
The Maximum Allowable Carryover (MACO) is fundamental to cleaning validation in GMP pharmaceutical manufacturing. When shared equipment is used to manufacture different products sequentially, regulatory agencies require demonstration that residues from the preceding product (Product A) do not compromise the safety or quality of the subsequent product (Product B). MACO establishes a scientifically defensible limit for the maximum amount of Product A residue that may remain on equipment surfaces before Product B manufacturing begins.
Cleaning validation scientists and quality assurance personnel perform MACO calculations during manufacturing process development and annually during regulatory reviews. The calculation is required by FDA guidance (21 CFR 211.67 on equipment design and use), EMA/CHMP/CVMP/SWP/169430/2012 on cleaning validation, and PIC/S guidelines. APIC (American Pharmaceutical Industry Chemistry) has published recommended calculation methodologies. The MACO value directly governs the acceptance limits for all subsequent analytical testing methods—swab sampling, rinse sampling, and non-specific methods like TOC—ensuring that monitoring programs are scientifically justified.
Four distinct calculation methods are recognized: the Therapeutic Dose method (most conservative, based on minimum therapeutic daily dose), the 10 ppm rule-of-thumb method (simplified but less justified), the Health-Based Exposure Limit (HBEL) or Acceptable Daily Exposure (ADE) method (toxicologically derived), and the LD50/NOEL method (uses No Observable Effect Level from animal studies with safety factors). The most restrictive MACO value governs actual equipment sampling and acceptance limits.
Four Recognized Methods for MACO Calculation:
The therapeutic dose method calculates the maximum residue of Product A that would constitute one minimum therapeutic dose of Product A in a minimum batch of Product B, then applies a safety factor (typically 1000) to account for population variability and uncertainty. This is the most conservative and most widely accepted approach by regulatory agencies.
A simplified approach assuming 10 parts per million of Product A in Product B is acceptable for most non-toxic products. Less scientifically justified than other methods but historically accepted for dedicated equipment. Result is in milligrams.
When a toxicologically derived Acceptable Daily Exposure (ADE) or Permitted Daily Exposure (PDE) is available for Product A, the MACO is calculated by allowing the maximum daily residue that equals the ADE when a patient takes the maximum daily dose of Product B. This method is modern, scientifically robust, and recommended by EMA guidance.
Uses published No Observable Effect Level (NOEL) from animal studies (typically mg/kg/day). Scaled to human body weight (default 70 kg) with application of a safety factor and normalization per the reference body weight used in toxicology (70 kg). Requires access to animal study data.
Governing MACO: The actual MACO used for cleaning validation acceptance limits is the minimum value of all calculated methods. This ensures the most conservative (most protective) limit is applied.
| Symbol | Variable | Units | Description |
|---|---|---|---|
| MinTDDA | Minimum Therapeutic Daily Dose of Product A | mg/day | The lowest therapeutic dose of Product A prescribed to patients. Used in Therapeutic Dose method. From approved product label or clinical literature. |
| MBSB | Minimum Batch Size of Product B | g or mL | The smallest batch quantity of Product B manufactured on shared equipment. Used to calculate residue concentration. Conservative practice uses smallest anticipated batch. |
| MaxDDB | Maximum Daily Dose of Product B | g/day | The highest therapeutic daily dose of Product B. Used to calculate patient exposure to residues from contaminated Product B. |
| SF | Safety Factor | dimensionless | Multiplication factor applied to account for population variability, inter-species differences, and study-to-clinical differences. Typically 1000 (10 for inter-species × 10 for intra-species variability). Range 100–10,000. |
| ADEA | Acceptable Daily Exposure of Product A | mg/day | Toxicologically derived daily exposure limit for Product A residue. Equivalent to PDE (Permitted Daily Exposure) per EMA. From qualified toxicologist review or published guidance. |
| NOEL | No Observable Effect Level | mg/kg/day | The highest dose in animal toxicity studies that produced no adverse effects. From published or internal toxicology studies. Used in LD50/NOEL method. |
| BW | Body Weight | kg | Human reference body weight for dose scaling. Default 70 kg (adult average). Range 40–100 kg depending on population. |
| 10 ppm | 10 Parts Per Million Rule | mg/mg | Simplified threshold: 10 mg of Product A residue per 1,000,000 mg (1 million mg) of Product B is acceptable. Constant value 0.00001 or 10 ppm. |
Scenario: A contract manufacturing facility produces both Lisinopril tablets (antihypertensive, Product A) and Metformin tablets (antidiabetic, Product B) on the same rotary tablet press and in the same capsule filling line. The manufacturing team must establish MACO before performing cleaning validation studies. Lisinopril minimum therapeutic dose (MinTDD) is 5 mg/day (lowest marketed dose). Metformin minimum batch size is 100,000 g (100 kg tablets per batch). Metformin maximum daily dose is 4 g/day. Lisinopril has published ADE of 0.15 mg/day and animal NOEL of 25 mg/kg/day from 90-day rat studies. Safety factor is 1000 (standard for scaling animal data to humans).